NYXH

Nyxoah SA
CAPPED RATING

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah SA (NYXH) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A-); its weakest is Momentum (D-). The rating has held at C+ for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
A-
Factor Score 4.1 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
D-
Factor Score 1.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.0
EV / EBITDA -0.8
Rev Growth YoY 365.0%
Gross Margin 61.1%
Price Return 3M -44.8%
Price Return 12M -84.2%
Catalyst Signal 0.00
Market Cap $91.2M
TTM Revenue $28.9M
Price / Sales 3.2
ROE -151.8%

Historical Factor Score Progression

Held C+ for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) A- (4.1) B- (2.9) D- (1.1) C+ (2.6) C+ (2.8)
2026-11-06 B- (3.0) A (4.3) B- (3.0) D- (1.1) C+ (2.7) C+ (2.8)
2026-10-30 B- (3.0) A (4.2) B- (3.0) D (1.2) C+ (2.7) C+ (2.8)
2026-10-23 B- (3.0) A (4.2) B- (3.0) D- (1.0) C+ (2.6) C+ (2.8)
2026-10-16 B- (3.0) A (4.2) B- (3.0) D (1.5) C+ (2.6) B- (2.9)
Page 1 of 4